Morgan Stanley analyst Sean Laaman assumed coverage of Jazz Pharmaceuticals (JAZZ) with an Overweight rating and a price target of $183, up from $175. The firm model higher oxybate revenue than the Street consensus and “more meaningful potential” from Ziihera in first-line gastroesophageal adenocarcinoma, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Backed by Strong Growth Prospects and Strategic Focus
- Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
- Jazz Pharmaceuticals price target raised to $230 from $220 at Truist
- Strategic Acquisition of Chimerix Enhances Jazz Pharmaceuticals’ Oncology Portfolio and Supports Buy Rating
- Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel